First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate
New England Journal of Medicine · 17.07.2025 · 393 (3) · 231-242
DOI: 10.1056/nejmoa2501443 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift New England Journal of Medicine, erschienen am 17.07.2025. Verfasst von Vivienne Kahlmann und 23 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence for Interstitial Lung Diseases and Sarcoidosis (member of the European Reference Network on Rare Respiratory Diseases), Departme…. Hauptthemen laut MEDLINE: Glucocorticoids, Immunosuppressive Agents, Methotrexate, Prednisone. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Lung Foundation Netherlands.
Abstract (Originalsprache)
BACKGROUND: Prednisone is currently recommended as the first-line treatment for pulmonary sarcoidosis but is associated with many side effects. Methotrexate, which is recommended as a second-line treatment, appears to have fewer side effects than prednisone but a slower onset of action. Data are needed on the efficacy and side-effect profile of methotrexate as compared with prednisone as first-line treatment for pulmonary sarcoidosis. METHODS: In this multicenter, open-label, noninferiority trial involving patients with pulmonary sarcoidosis who had not previously received treatment, we randomly assigned patients, in a 1:1 ratio, to receive prednisone or methotrexate according to a prespecified treatment schedule. The primary end point was the mean change from baseline to week 24 in the percentage of the predicted forced vital capacity (FVC), as estimated with the use of mixed models for repeated measures. The noninferiority margin for the primary end point was 5 percentage points. RESULTS: Of the 138 patients who underwent randomization, 70 were assigned to receive prednisone and 68 to receive methotrexate. The unadjusted mean change from baseline to week 24 in the percentage of the predicted FVC was 6.75 percentage points (95% confidence interval [CI], 4.50 to 8.99) in the prednisone group and 6.11 percentage points (95% CI, 3.72 to 8.50) in the methotrexate group. Methotrexate was noninferior to prednisone with regard to the primary end point, with an adjusted between-group difference of -1.17 percentage points (95% CI, -4.27 to 1.93). Adverse events occurred in a similar percentage of patients in the two trial groups. Weight gain, insomnia, and increased appetite were the most common adverse events with prednisone, and nausea, fatigue, and any abnormal liver-function test were among the most common adverse events with methotrexate. CONCLUSIONS: In patients with pulmonary sarcoidosis, initial treatment with methotrexate was noninferior to that with prednisone with regard to the change from baseline to week 24 in the percentage of the predicted FVC. Differences in the side-effect profile between methotrexate and prednisone may inform shared decision making by providers and patients about the appropriate treatment approach. (Funded by the Dutch Lung Foundation; PREDMETH ClinicalTrials.gov number, NCT04314193.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Excellence for Interstitial Lung Diseases and Sarcoidosis (member of the European Reference Network on Rare Respiratory Diseases), Department of Respiratory Medicine, Erasmus Medical Center, University Medical…
- Interstitial Lung Disease Center of Excellence (member of the European Reference Network on Rare Respiratory Diseases), St. Antonius Hospital, Nieuwegein, the Netherlands.
- Division of Heart and Lungs, University Medical Center, Utrecht, the Netherlands.
- Department of Respiratory Medicine, Zuyderland Medical Center, Heerlen, the Netherlands.
- Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.
- Department of Pulmonary Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
ORCID-Profile: Marlies S Wijsenbeek
Förderung
- Lung Foundation Netherlands
Zitieren
APA
Kahlmann, V., Janssen Bonás, M., Moor, C. C., Grutters, J. C., Mostard, R. L. M., van Rijswijk, H. N. A. J., van der Maten, J., Marges, E. R., Moonen, L. A. A., Overbeek, M. J., Koopman, B., Loth, D. W., Nossent, E. J., Wagenaar, M., Kramer, H., Wielders, P. L. M. L., Bonta, P. I., Walen, S., Bogaarts, B. A. H. A., …, & PREDMETH Collaborators (2025). First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. New England Journal of Medicine, 393(3), 231-242. https://doi.org/10.1056/nejmoa2501443
Vancouver
Kahlmann V, Janssen Bonás M, Moor CC, Grutters JC, Mostard RLM, van Rijswijk HNAJ, et al. First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate. New England Journal of Medicine. 2025;393(3):231-242. doi:10.1056/nejmoa2501443
BibTeX
@article{Kahlmann2025,
author = {Kahlmann, Vivienne and Janssen Bonás, Montse and Moor, Catharina C and Grutters, Jan C and Mostard, Rémy L M and van Rijswijk, Henricus N A J and van der Maten, Jan and Marges, Emiel R and Moonen, Linda A A and Overbeek, Maria J and Koopman, Bart and Loth, Daan W and Nossent, Esther J and Wagenaar, Michiel and Kramer, Henk and Wielders, Pascal L M L and Bonta, Peter I and Walen, Stefan and Bogaarts, Brigitte A H A and Kerstens, René and Overgaauw, Mayka and Veltkamp, Marcel and Wijsenbeek, Marlies S and PREDMETH Collaborators, PREDMETH Collaborators},
title = {First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {3},
pages = {231--242},
doi = {10.1056/nejmoa2501443}
}
EUVIMED